OAT1 Polyclonal Antibody

Multiple cysteine residues are necessary for proper targeting to the plasma membrane.,Involved in the renal elimination of endogenous and exogenous organic anions. Functions as organic anion exchanger when the uptake of one molecule of organic anion is coupled with an efflux of one molecule of endogenous dicarboxylic acid (glutarate, ketoglutarate, etc). Mediates the sodium-independent uptake of 2,3-dimercapto-1-propanesulfonic acid (DMPS) (By similarity). Mediates the sodium-independent uptake of p-aminohippurate (PAH), ochratoxin (OTA), acyclovir (ACV), 3'-azido-3-'deoxythymidine (AZT), cimetidine (CMD), 2,4-dichloro-phenoxyacetate (2,4-D), hippurate (HA), indoleacetate (IA), indoxyl sulfate (IS) and 3-carboxy-4-methyl-5-propyl-2-furanpropionate (CMPF), cidofovir, adefovir, 9-(2-phosphonylmethoxyethyl) guanine (PMEG), 9-(2-phosphonylmethoxyethyl) diaminopurine (PMEDAP) and edaravone sulfate. PAH uptake is inhibited by p-chloromercuribenzenesulphonate (PCMBS), diethyl pyrocarbonate (DEPC), sulindac, diclofenac, carprofen, glutarate and okadaic acid (By similarity). PAH uptake is inhibited by benzothiazolylcysteine (BTC), S-chlorotrifluoroethylcysteine (CTFC), cysteine S-conjugates S-dichlorovinylcysteine (DCVC), furosemide, steviol, phorbol 12-myristate 13-acetate (PMA), calcium ionophore A23187, benzylpenicillin, furosemide, indomethacin, bumetamide, losartan, probenecid, phenol red, urate, and alpha-ketoglutarate.,PTM:Glycosylated. Glycosylation at Asn-113 may occur at a secondary level. Glycosylation is necesssary for proper targeting of the transporter to the plasma membrane.,Belongs to the major facilitator superfamily. Organic cation transporter family.,tissue specificity:Strongly expressed in kidney and to a lower extent in liver, skeletal muscle, brain and placenta. Found at the basolateral membrane of the proximal tubule.,

The OAT1 Polyclonal Antibody is a highly specific and sensitive tool designed for the detection and quantification of Organic Anion Transporter 1 (OAT1) protein expression. This antibody is produced using a polyclonal approach, ensuring a diverse range of antibodies that target different epitopes of the OAT1 protein.

The OAT1 Polyclonal Antibody has been rigorously validated for its specificity and sensitivity in various applications, including Western blotting, immunohistochemistry, and immunofluorescence. It exhibits minimal cross-reactivity with other related proteins, ensuring accurate and reliable results.

With its high affinity and specificity, the OAT1 Polyclonal Antibody enables researchers to study the expression and localization of OAT1 in various tissues and cell types. It provides valuable insights into the role of OAT1 in drug transport and metabolism, as well as its potential implications in various diseases and disorders.

The OAT1 Polyclonal Antibody is supplied as a liquid formulation, making it easy to use and store. It is available in different sizes to accommodate various experimental needs. Each batch of antibody undergoes strict quality control measures to ensure consistent performance and reproducibility.

In summary, the OAT1 Polyclonal Antibody is a reliable and versatile tool for the investigation of OAT1 protein expression. Its high specificity, sensitivity, and diverse epitope recognition make it an essential component in the study of drug transport and metabolism, as well as its potential clinical implications.